Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (JPRN-jRCTs041250076) titled 'JALSG-AML224-PIF' on Aug. 12.
Study Type: Interventional
Study Design:
randomized controlled trial, open(masking not used), active control, parallel assignment, treatment purpose
Primary Sponsor: Kiyoi Hitoshi
Condition:
AML patients who do not achieve complete remission after a single course of induction chemotherapy
Intervention:
Eligible patients will be randomized to receive either venetoclax plus azacitidine or conventional intensive chemotherapy for remission induction and consolidation therapy.
Recruitment Status: Recruiting
Phase: 3
Date of First Enrollment: 12/08/2025
Target Sample Size:...